National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES.

1955. No. 40.

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth, of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

Dated this first

day of June , 1955.

W. J. Slim

Governor-General.

By His Excellency's Command,

Minister of State for Health.

Amendments of the National Health (Pharmaceutical Benefits) Regulations. 

Commencement.

1. These Regulations shall come into operation on the first day of June, 1955.

Interpretation.

2. Regulation 2 of the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting from sub-regulation (1.) the definition of "entitlement card"; and

(b) by omitting from that sub-regulation the definition of "pension number" and inserting in its stead the following definition:—

" 'pension number', in relation to a pensioner, means his pension number appearing on an entitlement card issued to him by the Commonwealth for the purposes of Part IV. and Part VII. of the Act;".

General pharmaceutical benefits.

3. Regulation 8 of the National Health (Pharmaceutical Benefits) Regulations is amended by omitting from sub-regulation (3.) the words—

"Quinine Bisulphate.

Quinine Dihydrochloride.

Quinine Hydrochloride.

Quinine Sulphate".

and inserting in their stead the words—

"Dienoestrol.

Quinine Bisulphate.

Quinine Dihydrochloride.

Quinine Hydrochloride.

Quinine Sulphate.

Stilboestrol".

* Notified in the Commonwealth Gazette on ,1955.

 Statutory Rules 1954, No. 54, as amended by Statutory Rules 1954, Nos. 77, 78, 93, 95 and 128.

2234/55.—Price 8d. 10/24.5.1955.

4. Regulations 11 and 12 of the National Health (Pharmaceutical Benefits) Regulations are repealed and the following regulations inserted in their stead:—

Forms of pensioner pharmaceutical benefits.

"11.— (1.) A drug or medicinal preparation prescribed for supply in the form of a cachet, pill or tablet is not a pensioner pharmaceutical benefit unless the form in which it is prescribed for supply is a form specified in relation to that drug or medicinal preparation in the Third Schedule or in a monograph in the British Pharmacopoeia.

"(2.) A drug or medicinal preparation prescribed for supply in capsule form is not a pensioner pharmaceutical benefit unless—

(a) the form of capsule is specified in relation to that drug or medicinal preparation in the Third Schedule or in a monograph in the British Pharmacopoeia; or

(b) the Director-General is of the opinion that the drug or medicinal preparation is of a particularly nauseous character and authorizes it to be prescribed in capsule form.

Maximum quantity or number of pharmaceutical benefits.

"12. The maximum quantity or number of units of a pharmaceutical benefit that may be prescribed for each supply of the benefit is—

(a) in the case of a general pharmaceutical benefit—the quantity or number of units specified in the First Schedule or the Second Schedule, as the case may be; and

(b) in the case of a pensioner pharmaceutical benefit—such quantity or number of units as is specified in relation to the form of that benefit in the Fourth Schedule".

Pharmaceutical benefits that may be supplied under section 93.

5. Regulation 13 of the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting sub-regulation (1.) and inserting in its stead the following sub-regulations:—

"(1.) The pharmaceutical benefits that a medical practitioner is authorized to supply for the purpose of section 93 of the Act are—

(a) the general pharmaceutical benefits the names or formulae of which are specified in the Fifth Schedule; and

(b) one of the following general pharmaceutical benefits:—

(i) Sulphonamides, Mixed, (B)—Three Sulphonamides; or

(ii) any other general pharmaceutical benefit that is a sulphonamide in tablet form and is approved by the Director-General as a pharmaceutical benefit which that medical practitioner is authorized to supply for the purpose of section 93 of the Act.

"(1a.) Subject to these Regulations, a medical practitioner may, for the purpose of section 93 of the Act, obtain—

(a) the pharmaceutical benefits the names or formulae of which are specified in the Fifth Schedule in the forms, but not exceeding the quantities, specified in that Schedule; and

(b) the pharmaceutical benefit referred to in paragraph (b) of the last preceding sub-regulation in tablet form not exceeding one hundred tablets.";

(b) by omitting from sub-regulation (3.) the words "specified in the Fifth Schedule, a medical practitioner may, for the purpose of section 93 of the Act," and inserting in their stead the words "a pharmaceutical benefit for the purpose of section 93 of the Act, a medical practitioner may"; and

(c) by omitting from sub-regulation (4.) the words "the maximum quantity or number of units specified in relation to that form in the Fifth Schedule" and inserting in their stead the words "the maximum quantity or number of units allowed by sub-regulation (1a.) of this regulation in relation to that form".

Supply of particular brand for purpose of section 93.

6. Regulation 17 of the National Health (Pharmaceutical Benefits) Regulations is amended by omitting the words "a pharmaceutical benefit specified in the Fifth Schedule" and inserting in their stead the words "a drug or medicinal preparation that is a pharmaceutical benefit for the purpose of section 93 of the Act".

Supply of pharmaceutical benefits on prescriptions.

7. Regulation 23 of the National Health (Pharmaceutical Benefits) Regulations is amended by omitting paragraphs (c) and (d) of sub-regulation (1.) and inserting in their stead the following paragraph:—"and (c) the prescription for its supply is dated within six months before the date of its presentation.".

Supply of pharmaceutical benefit on first presentation of prescription. Supply of repeats.

8. Regulation 25 of the National Health (Pharmaceutical Benefits); Regulations is amended by omitting from paragraph (b) the words "and initials that marking".

9. Regulation 26 of the National Health (Pharmaceutical Benefits) Regulations is amended by inserting in sub-regulation (2.), after the words "shall not", the words ",except as provided in the next succeeding regulation,".

Supply of repeats at the one time in special cases.

10. After regulation 26 of the National Health (Pharmaceutical Benefits) Regulations the following regulation is inserted:—

"26a.—(1.) Where a medical practitioner who writes a prescription for the repeated supply of a pharmaceutical benefit is satisfied that—

(a) the person for whose medical treatment the prescription is written is suffering from a chronic illness or is residing in a place remote from the approved pharmaceutical chemist nearest to that place of residence; and

(b) that person could not, without great hardship, obtain that pharmaceutical benefit on separate occasions,

the medical practitioner may, in the prescription, direct that the original supply of the pharmaceutical benefit and the repeated supplies be made at the one time.

"(2.) Subject to these Regulations, an approved pharmaceutical chemist to whom a prescription which is expressed to be made in accordance with this regulation is presented shall supply the pharmaceutical benefit prescribed in the prescription in accordance with the directions in the prescription".

Entitlement cards.

11. Regulation 40 of the National Health (Pharmaceutical Benefits) Regulations is repealed.

First Schedule.

12. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after item 6 the following item:—
"6a	Amodiaquine ..............	0.2 G .............................	tablet ............................	25	..";
(b) by omitting item 20;
(c) by inserting after item 24 the following item:—
"24a	Carbimazole ..............	5 mg ..............................	tablet ............................	100	1";
(d) by inserting after item 30 the following item:—
"30a	Desacetyl-lanatoside C ..	0.2 mg. per cc ................	2 cc. amp. .....................	6	1
0.25 mg. ........................	tablet ............................	40	l";
(e) by omitting item 72 and inserting in its stead the following item:—
"72	Glyceryl Trinitrate .. ..	1/200 gr. ........................	tablet ............................	100	1
1/150 gr. ........................	tablet ............................	100	1
1/130 gr. ........................	tablet ............................	100	1
1/100 gr. ........................	tablet ............................	100	1
1/65 gr. ..........................	tablet ............................	100	1
1/50 gr ...........................	tablet ............................	100	1";
(f) by inserting after item 80b the following item:—
"800	Hexamethonium Tartrate, Injection of	13.8%.. ..........................	1 cc. amp. .....................	10	1";
(g) by omitting items 92 and 93 and inserting in their stead the following item:—
"93	Leptazol, Injection of	......................................	1.1 cc. amp. ..................	6	..
......................................	3 cc. amp. .....................	2	..
......................................	5 cc. amp. .....................	1	..
(h) by omitting item 104 and inserting in its stead the following item:—
"104	Methoin ......................	0.1 G. ............................	tablet ............................	200	1";
(i) by inserting after item 105 the following item:—
"105a	Methylergometrine Tartrate ..	0.2 mg. per mil. ..............	0.5 mil. amp. .................	6	..
0.2 mg. per mil. ..............	1 mil. amp. ....................	6	..
0.125 mg. ......................	tablet ............................	25	..

 

(j) by inserting after item 114 the following item:—
"114a	noradrenaline ..........	1 in 1000 ......................................	2 mil. amp. ..................................................	6	..";
(k) by inserting after item 120 the following item:—
"120a	Papaveretum with Hyoscine Hydrobromide	Papaveretum 1/3 gr. ..	1 cc. amp. ....................................................	6	..
Hyoscine Hydrobromide 1/300 gr.
Papaveretum 1/3 gr. ..	1 cc. amp. ....................................................	6	..
Hyoscine Hydrobromide 1/150 gr.
Papaveretum 2/3 gr. ..	1 cc. amp. ....................................................	6	..;
Hyoscine Hydrobromide 1/150 gr.
(l) by omitting items 125, 126, 127 and 128 and inserting in their stead the following items:—
"125	Penicillin, Injection of ..	5,000 U. .......................................	amp. ............................................................	6	..
15,000 U. .....................................	amp. ............................................................	6	..
100,000 U. ....................................	amp. ............................................................	6	..
200,000 U. ....................................	amp. ............................................................	6	..
500,000 U. ....................................	amp. ............................................................	6	..
1,000,000 U. .................................	amp. ............................................................	6	..
1,500,000 U. .................................	amp. ............................................................	6	..
"126	Penicillin, Procaine, Aqueous Suspension of	300,000 U. ....................................	amp. ............................................................	6	..
400,000 U. ....................................	vial ..............................................................	6	..
600,000 U. ....................................	vial ..............................................................	6	..
900,000 U. ....................................	vial ..............................................................	6	..
1,000,000 U. .................................	vial ..............................................................	6	..
1,500,000 U. .................................	vial ..............................................................	6	..
"127	Penicillin, Procaine (Crystalline), Injection of	300,000 U. ....................................	amp. ............................................................	6	..
400,000 U. ....................................	amp. ............................................................	6	..
500,000 U. ....................................	amp. ............................................................	6	..
600,000 U. ....................................	amp. ............................................................	6	..
667,000 U. ....................................	amp. ............................................................	6	..
900,000 U. ....................................	amp. ............................................................	6	..
1,200,000 U. .................................	amp. ............................................................	6	..
1,500,000 U. .................................	amp .............................................................	6	..
"128	Penicillin, Procaine, Oily Injection of	300,000 U. per cc. .........................	1 cc. amp. ....................................................	6	..
600,000 U. ....................................	amp. ............................................................	6	..
1,000,000 U. .................................	amp. ............................................................	6	..
"128aa	Pentaerythritol Tetranitrate ..	10 mg. ..........................................	tablet ...........................................................	100	1
20 mg. ..........................................	tablet ...........................................................	100	1
30 mg. ..........................................	tablet ...........................................................	100	l";

 

(m) by inserting after item 145 the following item:—
"145a	Primaquine .........................................	15 mg.........................................	tablet ..................................................	14	..";
(n) by inserting after item 150 the following item:—
"150a	Prophenpyridiamine Para-aminosalicylate, injection of	25 mg. per cc. ............................	2 cc. amp. ...........................................	5	..";
(o) by omitting item161 and inserting in its stead the following item:—
"161	Sodium Chloride Physiological Solution for Injection	.................................................	2 cc. amp. ..........................................	6	1
.................................................	5 cc. amp. ..........................................	6	1
.................................................	10 cc. amp. ........................................	6	1
.................................................	10 cc. vial ..........................................	2	1
.................................................	20 cc. amp. ........................................	6	1
.................................................	50 cc. amp. ........................................	3	1
.................................................	1 litre bottle .......................................	2	1"; and
(p) by omitting item174 and inserting in its stead the following item:—
"174	Sulpharsphenamine, Injection of	0.15 G. ......................................	amp. ..................................................	2	1
0.3 G. ........................................	amp. ..................................................	2	1
0.45 G. ......................................	amp. ..................................................	2	1
0.6 G. ........................................	amp. ..................................................	2	1"

Second Schedule.

13. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting item 1 and inserting in its stead the following item:—
"1	aureomycin ........................................	50 mg. ..............................	capsule .................	25	..	Acute amoebic dysentery
100 mg. ............................	capsule .................	25	..	Acute and sub-acute bacterial endocarditis-streptococcus faecalis
250 mg. ............................	capsule .................	16	..
100 mg. ............................	vial .......................	6	..	Leptospirosis
Pneumonia that has not responded to penicillin or sulphonamides
Psittacosis
Scrub typhus
Staphylococcal infections that do not respond to penicillin
Urinary tract infections due to streptococcus faecalis";

 

(b) by omitting item 4 and inserting in its stead the following item:—
"4	Chloramphenicol ..........................	0.125 G. .......................	capsule ..........................	16	..	Typhoid fever
0.25 G. .........................	capsule ..........................	16	..	Brucellosis
Typhus and other rickettsial diseases
Scrub typhus
Influenzal meningitis
Granuloma inguinale
Lymphogranuloma venereum Whooping cough (haemophilus pertussis)
Infections due to haemophilus influenza
Acute laryngo-tracheo-bronchitis
Salmonella infections
Severe gastro-enteritis in children
Staphylococcal infections that do not respond to either penicillin or aureo-mycin
Urinary tract infections due to gram negative bacilli that do not respond to sulphonamides
Meningitis due to bacterium coli if other forms of treatment are unsuccessful";
(c) by omitting items 6, 7 and 8 and inserting in their stead the following items:—
"6	Cortisone Acetate .......................	25 mg. ...........................	tablet ..............................	40	1	Acute rheumatic carditis
25 mg. per cc. ................	10 cc. vial .......................	l	1	Addison's disease
25 mg. per cc. ................	20 cc. vial .......................	1	..	Total adrenalectomy
50 mg. per cc. ................	10 cc. vial .......................	1	..	Status asthmaticus
"6a	Cyanocobalamin..........................	10 γ per cc. ....................	1 cc. amp. .......................	12	1	Established megalocytic anaemias
20 γ per cc. ....................	1 cc. amp. .......................	12	l
50 γ per cc. ....................	1 cc. amp. .......................	6	1
50 γ per cc. ....................

10 cc. vial .......................	1	..
100 γ per cc. ..................	1 cc. amp. .......................	6	1
100 γ per cc. ..................	10 cc. vial .......................	1	..
200 γ per cc. ..................	1 cc. amp. .......................	1	..
1,000 γ per cc. ................	1 cc. amp. .......................	1	..
1,000 γ per cc. ................	10 cc. vial .......................	1	..

 

"7	Deoxycortone Acetate, Aqueous Injection of	5 mg. .............................	amp. ............................	5	..	Addison's disease
		50 mg. ...........................	amp. ............................	1	..
"8	Deoxycortone Acetate, Aqueous Suspension of	25 mg. ...........................	amp. ............................	1	..	Addison's disease";
(d) by inserting after item 13a the following items:—
"13b	Oxytetracycline .. ..	50 mg. ...........................	capsule .........................	25	..	Acute amoebic dysentery
100 mg. .........................	capsule .........................	25	..	Acute and sub-acute bacterial endocarditis-streptococcus faecalis
250 mg. .........................	capsule .........................	16	..
50 mg. ...........................	tablet ............................	25	..
100 mg. .........................	tablet ............................	25	..	Staphylococcal infections that do not respond to penicillin
250 mg. .........................	tablet ............................	16	..
100 mg. .........................	vial ...............................	6	..
250 mg. per 10 cc. ..........	10 cc. vial .....................	6	..	Pneumonia that has not responded to penicillin or sulphonamides
Psittacosis
Urinary tract infections due to streptococcus faecalis Scrub typhus
Leptospirosis
"13c	Oxytetracycline Oral Suspension	0.25 G. per 5 cc. .............	1 fl. oz. bottle ...............	1	..	Any disease or purpose specified in this column in relation to oxytetracycline";
(e) by omitting items 26 and 27; and
(f) by omitting items 33 and 34 and inserting in their stead the following items:—
"33	Tetracycline .. ..	50 mg. ............................	capsule .........................	25	..	Any disease or purpose specified in this column in relation to aureomycin
100 mg. ..........................	capsule .........................	25	..
250 mg. ..........................	capsule .........................	16	..
50 mg. ............................	tablet ............................	25	..
100 mg. ..........................	tablet ............................	25	..
250 mg. ..........................	tablet ............................	16	..
100 mg. ..........................	vial ...............................	6	..
100 mg. ..........................	I. M. vial .......................	6	..
250 mg. ..........................	vial ...............................	6	..
"34	Tetracycline Granules	75 G. ..............................	bottle ............................	1	..	Any disease or purpose specified in this column in relation to aureomycin
"35	Tetracycline Paediatric Drops	100 mg. per cc. ...............	10 cc. vial ....................	1	..		Any disease or purpose specified in this column in relation to aureomycin".

 

Third Schedule.

14. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting item 34; and

(b) by inserting after item 136 the following item:—

"136a Tabeilae Gentian Violet".

Fifth Schedule.

15. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting: the figures and words—

"177 Sulphonamides, Mixed, (B)—  Three Sulphonamides Tablet 100".

Printed for the Government of the Commonwealth by A. J. Arthur at the Government Printing Office, Canberra.